Market Place
Sourcing Support
Biomarin Pulls Gene Therapy Roctavian Off The Market
24 Feb 2026 //
FIERCE PHARMA
Biomarin Names Arpit Davé Chief Digital & Information Officer
12 Jan 2026 //
PR NEWSWIRE
Biomarin Pharma Plans To Divest Struggling Gene Therapy
27 Oct 2025 //
REUTERS
BioMarin Present New Bone Health Data at American Society Meeting
08 Sep 2025 //
PR NEWSWIRE
Sanofi snags BioMarin Leader to Serve as CMO
26 Aug 2025 //
FIERCE BIOTECH
BioMarin Touts Pipeline Asset as Potential Voxzogo Replacement
05 Aug 2025 //
FIERCE PHARMA
BioMarin scraps pre-clinical PKU drug over weak immunogenicity
05 Aug 2025 //
BIOSPACE
BioMarin Boosts 2025 Guidance After Strong Q2 Revenue and Margin
04 Aug 2025 //
PR NEWSWIRE
BioMarin appoints Ian T. Clark to Board of Directors
01 Aug 2025 //
PR NEWSWIRE
BioMarin Schedules Q2 2025 Financial Results Call and Webcast
22 Jul 2025 //
PR NEWSWIRE
BioMarin Completes Inozyme Acquisition
01 Jul 2025 //
PR NEWSWIRE
BioMarin Presents 5-Year Data on Roctavian at ISTH 2025
24 Jun 2025 //
PR NEWSWIRE
BioMarin Inks $270M Inozyme buyout, phase 3 prospect
17 May 2025 //
PRESS RELEASE
BioMarin Presents Data for Voxzogo in Children with Achondroplasia
12 May 2025 //
PR NEWSWIRE
BioMarin to Present at TD Cowen 45th Annual Healthcare Conference
25 Feb 2025 //
PR NEWSWIRE
BioMarin Reports Q4 and Full Year 2024 Results
19 Feb 2025 //
PR NEWSWIRE
BioMarin to add €60M lab to Irish manufacturing site
09 Dec 2024 //
FIERCE PHARMA
BioMarin Presents Real-World VOXZOGO Data at ESPE Meeting
16 Nov 2024 //
PR NEWSWIRE
BioMarin to Present Positive VOXZOGO Data for Achondroplasia in Children
18 Sep 2024 //
PR NEWSWIRE
BioMarin To Present At Morgan Stanley Healthcare Conference
29 Aug 2024 //
PR NEWSWIRE
BioMarin`s Roctavian struggles continue. Is a divestment in the future?
24 Apr 2024 //
ENDPTS
BioMarin lands 3 year deal for German coverage of gene therapy at $900K
28 Nov 2023 //
ENDPTS
Activist investor Elliott takes $1B stake in BioMarin: report
08 Nov 2023 //
FIERCE PHARMA
BioMarin First Person Treated Commercially with ROCTAVIAN Se.Hemophilia A in EU
30 Aug 2023 //
PR NEWSWIRE
US FDA approves BioMarin`s gene therapy for hemophilia A
30 Jun 2023 //
REUTERS
U.S. Food and Drug Administration Approves BioMarin`s ROCTAVIAN™
29 Jun 2023 //
PR NEWSWIRE
BioMarin wins approval for gene therapy to treat hemophilia A
29 Jun 2023 //
STAT NEWS
BioMarin to Present ROCTAVIAN Data from Hemophilia Gene Therapy Trial Program
22 Jun 2023 //
PRESS RELEASE
BioMarin`s hemophilia gene therapy may win over Europe: analysts
14 Jun 2023 //
FIERCE PHARMA
BioMarin debuts €38M expansion of its Irish operations
25 Apr 2023 //
FIERCE PHARMA
BioMarin to Share Data at 2023 ACMG Demonstrating Long-Term Benefit of VOXZOGO
14 Mar 2023 //
PRESS RELEASE
BioMarin, as expected, sees delay to FDA review of hemophilia gene therapy
08 Mar 2023 //
BIOPHARMADIVE
BioMarin Provides Update on FDA Review of ROCTAVIAN Gene Therapy
06 Mar 2023 //
PR NEWSWIRE
BioMarin preps for a potential gene therapy launch in US
03 Mar 2023 //
FIERCE PHARMA
BioMarin gets first access deal in EU for gene therapy Roctavian
12 Jan 2023 //
PHARMAPHORUM
BioMarin Announces Stable Annualized Bleed Control for ROCTAVIAN in PhII
08 Jan 2023 //
PRESS RELEASE
